PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

LIDODERM
(lidocaine patch 5%)

ZTLIDO
(lidocaine topical system)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization with Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Lidoderm
Lidoderm is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to **intact skin**.

ZTLido
ZTLido (lidocaine topical system) 1.8% is indicated for the relief of pain associated with post-herpetic neuralgia (PHN).

Compendial Uses
Pain associated with diabetic neuropathy[4,5,8]
Pain associated with cancer-related neuropathy[4,6,7]

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for any of the following: A) Pain associated with post-herpetic neuralgia, B) Pain associated with diabetic neuropathy, C) Pain associated with cancer-related neuropathy (including treatment-related neuropathy [e.g. neuropathy associated with radiation treatment or chemotherapy])

Quantity Limits apply.
90 patches/30 days.
270 patches/90 days.

REFERENCES

1. Lidoderm [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; November 2018.
2. ZTLido [package insert]. San Diego, CA: Scilex Pharmaceuticals Inc.; November 2018.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. http://online.lexi.com/. Accessed August 2019.
4. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. http://www.micromedexsolutions.com/. Accessed September 2018.
5. Barbano RL, Herrmann DN, Hart-Gouleau S, et al: Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. *Arch Neurol* 2004; 61:914-918.

6. National Comprehensive Cancer Network: Adult Cancer Pain V3.2019. National Comprehensive Cancer Network. Fort Washington, PA. 2008. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/pain.pdf. Accessed August 2019.
7. Vadalouca A, Raptis E, Moka E, et al. Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of Current Literature. World Institute of Pain *Pain Practice* 2011; 12(3):219-251.
8. Bril V., England J., Franklin G.M., et al. Evidence-based guideline: Treatment of painful diabetic neuropathy. Neurology 2011;76;1758. Available at www.neurology.org. Accessed August 2019.
9. Derry S, Wiffen PJ, Moore RA, et al. Topical lidocaine for neuropathic pain in adults (Review). *Cochrane Database Syst Rev* 2014. doi: 10.1002/14651858.CD010958.

